Lexaria Bioscience Corp (LEXX)

[Shawking]

https://letstoke.us19.list-manage.com/track/click?u=f2e0706764f99154e3a11feb5&id=cdea306711&e=9cbb5a4bc7
Lexaria Bioscience (NASDAQ: LEXX): dipped to $2.12 last week which is a market cap of $27 million.
On March 12, 2024, as LEXX was rallying strongly, I said I didn’t think LEXX’s market cap would fall
below $30 million and last week it did. Remember, LEXX has a hypertension solution approved by the
FDA for additional testing that is underway with early results expected shortly. It also has a diabetes/obesity that is probably a year from gaining FDA testing approval. There should be several results
oriented news releases this year. These are two potentially major projects, either one of which can
justify a $30 million market cap. As LEXX falls back, it gives investors a second chance to grab the ring.
If I believed LEXX was attractive at $3, I like it even more at around $2. I conclude that LEXX has the
potential to rally back strongly.